Open AccessTranslational aspects of cardiac cell therapy
Author(s) -
Chen ChengHan,
Sereti KonstantinaIoanna,
Wu Benjamin M.,
Ardehali Reza
Publication year - 2015
Publication title -
journal of cellular and molecular medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.44
H-Index - 130
eISSN - 1582-4934
pISSN - 1582-1838
DOI - 10.1111/jcmm.12632
Subject(s) - cell therapy , progenitor cell , reprogramming , mesenchymal stem cell , induced pluripotent stem cell , stem cell , medicine , bone marrow , myocyte , stem cell therapy , regeneration (biology) , cardiac function curve , clinical trial , clinical uses of mesenchymal stem cells , cell , cell type , bioinformatics , cancer research , adult stem cell , immunology , heart failure , microbiology and biotechnology , biology , pathology , endothelial stem cell , embryonic stem cell , in vitro , biochemistry , genetics , gene
Cell therapy has been intensely studied for over a decade as a potential treatment for ischaemic heart disease. While initial trials using skeletal myoblasts, bone marrow cells and peripheral blood stem cells showed promise in improving cardiac function, benefits were found to be short‐lived likely related to limited survival and engraftment of the delivered cells. The discovery of putative cardiac ‘progenitor’ cells as well as the creation of induced pluripotent stem cells has led to the delivery of cells potentially capable of electromechanical integration into existing tissue. An alternative strategy involving either direct reprogramming of endogenous cardiac fibroblasts or stimulation of resident cardiomyocytes to regenerate new myocytes can potentially overcome the limitations of exogenous cell delivery. Complimentary approaches utilizing combination cell therapy and bioengineering techniques may be necessary to provide the proper milieu for clinically significant regeneration. Clinical trials employing bone marrow cells, mesenchymal stem cells and cardiac progenitor cells have demonstrated safety of catheter based cell delivery, with suggestion of limited improvement in ventricular function and reduction in infarct size. Ongoing trials are investigating potential benefits to outcome such as morbidity and mortality. These and future trials will clarify the optimal cell types and delivery conditions for therapeutic effect.